top of page

ADVANCING THE STANDARD
OF CARE IN OPHTHALMICS

About

Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction.  As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals. 


Our lead asset, PDP-716, is a once-daily brimonidine for ocular hypertension and open angle glaucoma. The NDA submission was accepted with a PDUFA target action date of August 4, 2023.  

 

Our next asset, SDN-037, is a twice daily topical difluprednate for post-surgical inflammation and pain.  Each product utilizes a unique, proprietary, extended release technology that is patent protected through at least 2036.

 

PDP-716, SDN-037, and TearActTM delivery technology were licensed by Visiox from Sun Pharma Advanced Research Company Ltd.

About
Pipeline

Pipeline

PDP-716

Once-daily brimonidine for ocular hypertension and open angle glaucoma utilizing our patented TearAct™ fine resin technology

Picture1.png

SDN-037

Twice daily topical difluprednate for post-surgical inflammation and pain utilizing our patented TJM micellar platform

Picture3.png

Visiox is leading the development and commercialization of best-in-class formulations of well-known compounds treating highly prevalent conditions of the eye.  Our two lead assets are preparing for launch, and we are aggressively building our portfolio.

Picture 5.png

Meet The Team

RB-4919fmask2.JPG

Ryan Bleeks

Chief Executive Officer & Director

LinkedIn_logo_initials.png
MDerby Headshot.jpg

Michael Derby

Founding Investor & Executive Chairman

LinkedIn_logo_initials.png
zzch1.jpeg

Zachary Rome

Co-founder &
Director

LinkedIn_logo_initials.png
Vicente.jpeg

Vicente Anido

Strategic Advisor

LinkedIn_logo_initials.png
Ehsan.jpeg

Ehsan Sadri, MD

Advisor & Director

LinkedIn_logo_initials.png
Tom Mitro -  Fav Headshot (002) (1).JPG

Tom Mitro

Director

LinkedIn_logo_initials.png
Matossian Headshots - Kasey Ivan Photography-2.png

Cynthia Matossian, MD, FACS

Chief Medical Advisor

LinkedIn_logo_initials.png
Team
News
Contact
shutterstock_1728978160.png

Contact Us

303 S Broadway, Suite 125

Tarrytown, NY 10591 

Tel: 914-987-2876

info@visioxpharma.com

Thanks for submitting!

bottom of page